AVEO Pharmaceuticals (AVEO) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
UPDATE: RBC Capital Upgrades AVEO Pharmaceuticals (AVEO) to Sector Perform
March 9, 2015 6:50 AM EDT(Updated - March 9, 2015 8:05 AM EDT)
RBC Capital upgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Underperform to Sector Perform with a price target of $3.00 (from $2.00). Analyst Adnan Butt thinks shares could begin reflecting pipeline optionality.
"Since the setback with tivozanib in renal cancer,... More
AVEO Pharmaceuticals (AVEO) Reports FOLFOX6 Combo Phase 2 Met Intent to Treat Endpoint; Will Present Data
March 6, 2015 7:09 AM ESTAVEO Oncology (NASDAQ: AVEO) announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer (CRC). The presentation, titled Neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib + mFOLFOX6 versus bevacizumab + mFOLFOX6 in metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC Phase 2 trial, will be presented in a poster session today at the American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization... More
AVEO Pharmaceuticals (AVEO) Moves into Overbought Territory
March 5, 2015 12:32 PM ESTAs AVEO Pharmaceuticals (NASDAQ: AVEO) traders pare some gains, more might be in the works amid recent trading data.
The 14-day money flow index in AVEO is at 93 percent, indicating that the stock was vastly overbought. The last time shares... More
